0000000000860844

AUTHOR

Uwe Verthein

showing 2 related works from this author

Maintenance treatment for opioid dependence with slow‐release oral morphine: a randomized cross‐over, non‐inferiority study versus methadone

2012

Aims To compare the efficacy of slow-release oral morphine (SROM) and methadone as maintenance medication for opioid dependence in patients previously treated with methadone. Design Prospective, multiple-dose, open label, randomized, non-inferiority, cross-over study over two 11-week periods. Methadone treatment was switched to SROM with flexible dosing and vice versa according to period and sequence of treatment. Setting Fourteen out-patient addiction treatment centres in Switzerland and Germany. Participants Adults with opioid dependence in methadone maintenance programmes (dose ≥50 mg/day) for ≥26 weeks. Measurements The efficacy end-point was the proportion of heroin-positive urine samp…

AdultMaleNarcoticsMethadone maintenanceretention ratePopulationslow-release oral morphineAdministration OralMedicine (miscellaneous)Maintenance ChemotherapyMedication AdherencemethadoneOpiate Substitution TreatmentmedicineHumanseducationMorphine Derivativeseducation.field_of_studyCross-Over StudiesMorphinemaintenance treatmentCodeinebusiness.industryCodeineResearch ReportsOpioid use disorderOpiate Substitution TreatmentMiddle AgedOpioid-Related Disordersmedicine.diseaseCrossover studyPsychiatry and Mental healthTreatment OutcomeOpioidDelayed-Action PreparationsAnesthesiaFemaleDose–responsebusinessopioid addictionMethadonemedicine.drugAddiction
researchProduct

Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence

2014

Opioid substitution treatment (OST) for opioid dependence may be limited by adverse events (AEs). Increasing the range of therapeutic options optimizes outcomes and facilitates patient management. An international, multi-center, two-phase study investigated the efficacy and safety of slow-release oral morphine (SROM) versus methadone in patients receiving methadone therapy for opioid dependence. In phase 1 (two way cross-over, 11 weeks each period) patients were randomized to SROM or methadone oral solution. In phase 2 (25 weeks), patients continued treatment with SROM (group A) or switched from methadone to SROM (group B). In total, 211 out of 276 completed phase 1 and 198 entered phase 2 …

AdultMaleInternational CooperationAdministration OralMedicine (miscellaneous)QT intervalHeroinOpiate Substitution TreatmentHumansMedicineIn patientOral morphineAdverse effectCross-Over StudiesMorphinebusiness.industryOpioid-Related DisordersEuropePsychiatry and Mental healthClinical PsychologyTreatment OutcomeOpioidTolerabilityDelayed-Action PreparationsAnesthesiaFemalePshychiatric Mental HealthbusinessMethadonemedicine.drugMethadoneJournal of Substance Abuse Treatment
researchProduct